Vaccine Info

CoVepiT COVID-19 Vaccine

Last Reviewed
January 10, 2021

CoVepiT COVID-19 Vaccine Description

CoVepiT is a prophylactic vaccine candidate against COVID-19 based on optimized peptides selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2 in barrier tissues, the respiratory tract, and the lung.

The OSE Immunotherapeutics vaccine candidate incorporates optimized peptide fragments (neoepitopes) improved using artificial intelligence algorithms to increase immune response and induce strong memory T cell responses.

CoVepiT incorporates 11 optimized neoepitope targets chosen following bioinformatics analysis of more than 167 000 different SARS-CoV-2 sequences collected globally to ensure high stability of the chosen targets and potential to cover all initial and novel SARS-CoV-2 strains and variants.

The oral presentation given by Dr. Nicolas Poirier at the virtual 2020 Immunotherapy Congress, titled “CoVepiT: Multiple CD8 T-cell epitopes second-generation SARS-CoV-2 vaccine, long-term, lasting tissue-resident memory T cells,” is available on https://tinyurl.com/yx94gush.

Generated using the OSE’s Memopi vaccinal technology, which has already shown good tolerance and efficacy in a large number of cancer patients, these data build a strong basis to pursue the development of this 2nd generation of SARS-CoV-2 vaccine focused on memory CD8 T cell technology.

France based OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

CoVepiT COVID-19 Vaccine Indication

CoVepiT COVID-19 Vaccine candidate is indicated to respond to multiple parts of SARS-CoV-2, suggesting it will provide long-term protective immunity instead of transient protection provided by neutralizing antibodies.

CoVepiT is a prophylactic vaccine against COVID-19 based on optimized peptides selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2 in barrier tissues, respiratory tract, and the lung. The vaccine incorporates optimized peptide fragments (neoepitopes) improved using artificial intelligence algorithms to increase immune response and induce strong memory T cell responses.

CoVepiT COVID-19 Vaccine News

December 18, 2020 - OSE Immunotherapeutics announced that the Company had obtained funding of €5.2 million under the PSPC-COVID call for projects, operated on behalf of the French government by Bpifrance as part of the Programme d’investissements d’avenir and led by the Secrétariat général pour l’investissement, to support its development program on CoVepiT, its second-generation multi-target vaccine against COVID-19.

November 5, 2020 - OSE Immunotherapeutics announced the successful completion of its human ex vivo study with CoVepiT, a prophylactic vaccine based on optimized epitopes selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2, the virus that causes COVID-19. In parallel, OSE Immunotherapeutics gave an overview of the development of this multi-target vaccine at the World Immunotherapy Congress, or Festival of Biologics, held virtually November 2-6, 2020. This is the first presentation on a second-generation memory T cell COVID-19 vaccine at a scientific congress.

August 17, 2020 - OSE Immunotherapeutics announced the online publication in BioRxiv of positive data from preclinical and human ex vivo studies with CoVepiT, its prophylactic vaccine program based on optimized peptides selected to induce a lasting sentinel T lymphocyte immune response against SARS-CoV-2, the virus that causes COVID-19, in barrier tissues such as the respiratory tract and the lung.

August 14, 2020 - Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine. Data support potential as a novel and differentiated COVID-19 vaccine designed against multiple SARS-CoV-2 targets with technology known to induce memory T lymphocytes.

CoVepiT COVID-19 Vaccine Clinical Trial

A clinical Phase 1/2 is expected to start in Q1 2021.

CoVepiT is generated using OSE’s proprietary Memopi® technology, which has been validated for safety and efficacy through the step-1 of Phase 3 clinical phase of neoepitope vaccine Tedopi® in patients with non-small lung cancer.

The CoVepiT development program will be conducted within a consortium led by OSE Immunotherapeutics, in partnership with the teams of Prof. Eric Tartour, Head of the biological immunology department at the European Hospital Georges-Pompidou-APHP and Professor at the University of Paris, in charge of immune-monitoring, and with the teams of Prof. Odile Launay, Professor of infectious and tropical diseases at University of Paris and Coordinator of the Clinical Investigation.